{
  "image_filename": "figure_p4_det_3_007.png",
  "image_path": "FlublokPI/extracted/figures/figure_p4_det_3_007.png",
  "image_type": "Figure",
  "page_number": 4,
  "block_id": "det_3_007",
  "claim_id": "claim_006",
  "claim": "Flublok is produced using a novel production platform in which recombinant HA is expressed in insect cells using a baculovirus expression vector system (BEVS).",
  "supports_claim": false,
  "explanation": "A table comparing Flublok Quadrivalent (N=4303) versus a comparator (N=4301), showing numbers of cases (n), attack rates (% n/N), relative risk (RR), and relative vaccine efficacy (rVE % with 95% CI) for outcomes including all rtPCR-positive influenza, Influenza A, Influenza B, and culture-confirmed protocol-defined ILI. does not support the claim: the table presents clinical efficacy results and does not provide any information about the production platform or the use of insect cells and a baculovirus expression vector system for manufacturing Flublok.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table comparing Flublok Quadrivalent (N=4303) versus a comparator (N=4301), showing numbers of cases (n), attack rates (% n/N), relative risk (RR), and relative vaccine efficacy (rVE % with 95% CI) for outcomes including all rtPCR-positive influenza, Influenza A, Influenza B, and culture-confirmed protocol-defined ILI.",
    "evidence_found": null,
    "reasoning": "does not support the claim: the table presents clinical efficacy results and does not provide any information about the production platform or the use of insect cells and a baculovirus expression vector system for manufacturing Flublok.",
    "confidence_notes": null
  }
}